Publisher Correction: Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

Judith Feucht; Jie Sun; Justin Eyquem; Yu-Jui Ho; Zeguo Zhao; Josef Leibold; Anton Dobrin; Annalisa Cabriolu; Mohamad Hamieh; Michel Sadelain

doi:10.1038/s41591-019-0360-3

Publisher Correction: Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

Nat Med. 2019 Mar;25(3):530. doi: 10.1038/s41591-019-0360-3.

Authors

Affiliations

¹ Center for Cell Engineering and Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Zhejing, China.
³ Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Center for Cell Engineering and Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [email protected].

PMID: 30692700
DOI: 10.1038/s41591-019-0360-3

Abstract

In the version of this article originally published, there was an error in the legend for Extended Data Fig. 7. The legend for panel f was originally: "f, FACS analysis of IL7R^-, CD62L^- and CD45RA^- expression on TRAC-1928ζ and TRAC-1XX CAR T cells at day 63 post CAR infusion (representative for at least n = 3 mice per group in one independent experiment)." The legend should have been: "f, FACS analysis of IL7R⁺, CD62L⁺ and CD45RA⁺ expression on TRAC-1928ζ and TRAC-1XX CAR T cells at day 63 post CAR infusion (representative for at least n = 3 mice per group in one independent experiment)." The error has been corrected in the HTML and PDF versions of this article.

Publication types

Published Erratum